Media ReleaseCollaborate Against Cancer09 Nov 2020

National Oncology Alliance targets a 90 per cent survival rate for all Australian cancer patients by 2030

The National Oncology Alliance (NOA) – an alliance of patients, patient groups, clinicians, and the healthcare industry has developed a 2030 vision for cancer care in Australia, which puts patients at the centre of cancer care over the coming decade and beyond.

Breast cancer patients and survivors attend seminar
Photo Credit: SDI Productions via Getty Images.

More than 550,000 Australians are expected to die from cancer, between now and 2030 if nothing changes. But if we adapt, plan and reform the system to maximise the use of these new sciences, many thousands of these lives could be saved or at the very least significantly extended.

“Our understanding of cancer and how to treat it is changing at an astonishing rate. There is real hope that over the next decade cancer will transform from a death sentence to a chronic disease that allows patients to live long productive lives. Discoveries in genomics, immuno-oncology, regenerative therapy, precision therapy, radiation oncology and artificial intelligence are allowing us to understand each patient’s cancer like never before,” said Mr Richard Vines Chief Executive of Rare Cancers Australia and Founder of the Alliance.

The Vision 20-30 report offers a look at the emerging landscape of cancer science and articulates the urgent need for Australia to plan to maximise these new treatment possibilities. The report, developed by NOA in partnership with the Minderoo Foundation, identifies the opportunities and challenges that the Australian healthcare system will face in caring for Australians living with cancer over the next decade.

“In no other disease area are we presented with such a rare opportunity to save or improve the lives of so many Australians in need”

With input from more than 50 Australian experts, and consultation with over 500 members of the cancer community the Vision 20-30 report casts a national direction for how cancer care will evolve over the next ten years for all cancer patients – regardless of cancer type, patient geography or financial situation. It highlights the need for a long-term plan to help shape the future of cancer care and treatment and includes strategies that will facilitate timely and affordable access to the latest innovative treatments for all Australians.

Dr. Steve Burnell, CEO of Minderoo Foundation’s Collaborate against Cancer said, “Australia has achieved comparatively high survival rates for some cancer types but the rare and less common cancers, for example, account for 35% of cancer diagnoses, but 50% of cancer deaths. We need to find innovative ways to improve outcomes for all cancer patients. Minderoo Foundation is pleased to support the development of this vision and framework which will help drive greater collaboration across philanthropy, government, industry, research and clinical care – so that together we can make cancer non-fatal.”

“The goal is to achieve a greater than 90% survival rate across all cancer types and subtypes – regardless of rarity. For Australia to be a world leader in cancer care, a comprehensive framework for broader access to genomic testing and precision medicine from research into the clinical setting is needed to coordinate the work that is being undertaken by multiple players in this evolving field, Australia has already achieved greater than 90% five year survival for some cancers. We say, why not all?” said Mr. Vines.

The full version of the 20-30 Vision: Australian Cancer Futures Framework can be downloaded at

Minderoo Foundation
by Minderoo Foundation

Established by Andrew and Nicola Forrest in 2001, we are a modern philanthropic organisation seeking to break down barriers, innovate and drive positive, lasting change. Minderoo Foundation is proudly Australian, with eight key initiatives spanning from ocean research and ending slavery, to collaboration in cancer and community projects.

2 minute read
Share this article
Other Stories